Famciclovir

證據等級: L5

預測適應症: 9 個

Famciclovir: From Herpes Zoster/Genital Herpes to Post-infectious Neuralgia

One-Sentence Summary

Famciclovir is an established oral antiviral (a prodrug of penciclovir) used for varicella-zoster and herpes simplex virus infections such as herpes zoster, genital herpes, and herpes labialis. The TxGNN model’s top-ranked prediction for this drug is Post-infectious Neuralgia (essentially postherpetic neuralgia), but the evidence pack contains 0 literature records and only 2 clinical trials, neither of which actually tests famciclovir — both are graded “C” relevance (disease-population overlap only). This is currently a model-driven signal with mechanistic plausibility but no direct trial or literature support.

Quick Overview

Item	Content
Original Indication	Not captured in this dataset (`original_indications` is empty; famciclovir is generically known as an antiviral for herpes zoster, genital herpes, and herpes labialis, but this dataset carries no confirmed regulatory-label text — see data gap below)
Predicted New Indication	Post-infectious Neuralgia (postherpetic neuralgia)
TxGNN Prediction Score	99.75%
Evidence Level	L5 (reassessed — see note below)
Market Status (Taiwan/TFDA)	未上市 (Not marketed)
Number of Licenses	0 (no license records)
Recommended Decision	Hold

Note on Evidence Level and Decision: The evidence pack’s internal scoring field labels this candidate L2/”Proceed with Guardrails.” Applying the stated determination rules (≥2 completed Phase 3 RCTs = L1; 1 completed Phase 2/3 RCT = L2; observational/review = L3; preclinical/mechanism = L4; model-only = L5) to the actual evidence supplied — two trials, both testing other interventions (oxycodone; nerve block), neither completed nor evaluating famciclovir, zero literature — this candidate is more accurately L5, and the recommendation here is revised to Hold.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for famciclovir is not available in this dataset (data gap DG002). Based on established pharmacological knowledge, famciclovir is a prodrug of penciclovir: it is phosphorylated by viral (VZV/HSV) thymidine kinase and subsequently inhibits viral DNA polymerase, giving it direct antiviral activity against varicella-zoster virus (VZV) — the virus responsible for both chickenpox and, upon reactivation, herpes zoster (shingles).

Postherpetic neuralgia is the best-known complication of herpes zoster: persistent pain in the affected dermatome after the rash resolves. Because famciclovir suppresses VZV replication during the acute shingles episode, there is a plausible mechanistic pathway by which earlier/more effective antiviral treatment could reduce the incidence or severity of postherpetic neuralgia — an association also raised qualitatively in the evidence pack’s own rationale text (citing, without including, the Tyring et al. Phase 3 literature).

However, the clinical trial evidence actually retrieved for this specific pairing does not test famciclovir: NCT03120962 evaluates oxycodone, and NCT06798662 evaluates nerve blockade/pulsed radiofrequency — both are disease-population matches only (relevance grade C), not drug evidence. By contrast, within the same evidence pack, “chickenpox” (rank 7, VZV infection broadly) has markedly stronger direct evidence — a completed Phase 3 RCT comparing famciclovir head-to-head against aciclovir (NCT01327144) and a completed Phase 3 pediatric PK/safety study (NCT00098046), plus 20 supporting literature records. That signal is closer to the drug’s already-known antiviral spectrum than a genuinely novel indication, but it is far better substantiated than the top-ranked “post-infectious neuralgia” prediction and may warrant separate evaluation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03120962	NA	Unknown	140	Tests early oxycodone (not famciclovir) during acute herpes zoster for PHN prevention; disease-population overlap only (relevance grade C)
NCT06798662	NA	Not yet recruiting	120	Tests multimodal nerve block/pulsed radiofrequency (liposomal bupivacaine, ropivacaine) for acute herpes zoster pain, not famciclovir; disease-population overlap only (relevance grade C)

Neither trial evaluates famciclovir directly.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications are flagged as a Blocking data gap in this evidence pack — DG001 — meaning a formal S1 safety screen cannot be completed until this is resolved.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, and there is textbook-level mechanistic plausibility linking VZV-targeted antiviral therapy to reduced postherpetic neuralgia risk. However, none of the clinical trials retrieved for this pairing actually test famciclovir, and there is no supporting literature — the direct evidence base for this specific drug-disease pairing is effectively absent (L5).

To proceed, the following is needed:

TFDA package insert / label warnings and contraindications (DG001, blocking — required before any safety screening)
Confirmed original indication and mechanism-of-action data (DG002)
Direct clinical evidence testing famciclovir specifically for postherpetic-neuralgia prevention (e.g., re-query literature to retrieve the Tyring et al. Phase 3 studies referenced qualitatively but not included in this evidence pack)
Consider evaluating “chickenpox”/herpes zoster (rank 7) in parallel, given its substantially stronger direct evidence (completed Phase 3 head-to-head RCT vs. aciclovir, pediatric Phase 3 PK/safety study, 20 literature records)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.